Pedf derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity
Metrics: PDF 158 views | HTML 461 views | ?
Paloma Honrubia-Gómez1, María-Pilar López-Garrido2, Carmen Gil-Gas1, José Sánchez-Sánchez3, Carmen Alvarez-Simon1, Jorge Cuenca-Escalona4, Ana Ferrer Perez5, Enrique Arias6, Raul Moreno7, Francisco Sánchez-Sánchez2 and Carmen Ramirez-Castillejo1,4
1Stem Cell Laboratory, Departamento Ciencias Médicas, CRIB, UCLM, Albacete, Spain
2Genética Médica, Departamento de Ciencia y Tecnología Agroforestal y Genética, IDINE, UCLM, Albacete, Spain
3Current address: Unidad de Oncologia, Hospital de Almansa, Albacete, Spain
4Cancer Stem Cell Laboratory, HST Group, Biotechnology and V Biology Department, ETSIAAB, UPM, Madrid, Spain
5Current address: Oncology Division, Hospital Obispo Polanco, Teruel, Spain
6Departamento de Sistemas Informáticos, UCLM, Albacete, Spain
7UCAM, UCLM, Toledo, Spain
Francisco Sánchez-Sánchez, email: firstname.lastname@example.org
Carmen Ramirez-Castillejo, email: email@example.com
Keywords: colorectal cancer stem cells; cancer initiating cells; relapse; self-renewal inhibition; PEDF
Abbreviations: IC50: concentration of drug necessary to kill 50% of the cell population; CT: carboxi-terminal part of the PEDF protein; CTE: carboxi-terminal part of the PEDF protein with a change of a serine by a glutamic; PEDF: Pigmented epithelium derived factor
Received: March 19, 2018 Accepted: August 06, 2018 Published: April 26, 2019
Relapse after chemotherapy treatment depends on the cancer initiating cells (CICs). PEDF (Pigmented Epithelium Derived Factor) is an anti-angiogenic, neurotrophic and self-renewal regulator molecule, also involved in CICs biology. Acute and chronic exposition of colon cancer cell lines to CT/CTE PEDF-derived peptides decreased drug-resistance to conventional colorectal cancer treatments, such as oxaliplatin or irinotecan. We confirmed a reduction in the irinotecan and oxaliplatin IC50 doses for all tested tumour cell lines. After xenograft transplantation, CT/CTE treatments also produced a reduction in resistance to conventional chemotherapy treatments as in culture-assays. Metastatic capacity of these treated cell lines was also depleted. The PEDF signaling pathway could be a future therapeutic tool for use as an adjuvant therapy that decreases IC50 dosis, adverse effects and treatment costs. This pathway could also be involved in an increase of the time relapse in patients, decreased tumourigenicity, and decreased capacity to produce metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.